Author: Vivek Ramaswamy
I've said all along that we're building Axovant as a lasting company for the long run, not to hand over that upside to a pharma company in the future.
If we can validate our scientific bets in the clinic, if we can bring valuable new treatments to patients that need them, that will be our ultimate measure of success.
The thing in Alzheimer's disease to remember, and we remember this all the time at Axovant, is we don't fully understand the way the actual underlying disease works.
I'd encourage more young people to apply their talents beyond finance and consulting and to think about reshaping how medicines are brought to market and how the business is run.